Valuation : Autolus Therapeutics plc

Market Cap 596M 514M 485M 441M 825M 56.32B 831M 5.74B 2.23B 28.79B 2.24B 2.19B 94.59B P/E 2026 *
-2.78x
P/E 2027 * -3.28x
Enterprise Value 440M 380M 358M 326M 609M 41.58B 614M 4.24B 1.64B 21.26B 1.65B 1.62B 69.84B EV / Sales 2026 *
2.94x
EV / Sales 2027 * 2.7x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+2.68%
1 week-2.33%
Current month-1.91%
1 month+26.65%
3 months+42.28%
6 months+42.28%
Current year+15.83%
1 week 2.22
Extreme 2.22
2.38
1 month 1.8
Extreme 1.8
2.58
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
29/6/26 Free

Director

79,167 0.0477%
18/3/26 Other

Chief Executive Officer

6,917,877 4.1641%
18/3/26 Other

Chairman

280,000 0.1685%
Change 5-day change 1-year change 3-year change Capi.($)
+2.46%-2.33%+60.07%-26.59% 596M
-1.47%+3.98%+48.97%+2.06% 85.08B
-3.97%+2.40%+507.90%+33.69% 60.21B
+0.95%+0.93%-15.06%-34.62% 59.71B
-1.25%-6.13%-2.08%+33.18% 51.1B
-0.27%-0.90%+8.86%+169.09% 48.73B
+0.69%+0.61%+57.36%-16.31% 32.9B
-0.66%-0.29%+46.46%+101.27% 26.11B
+0.79%-6.56%-2.56%+192.31% 22.6B
+1.08%-1.92%+63.74%+112.60% 16.42B
Average -0.16%-2.17%+77.37%+56.67% 40.35B
Weighted average by Cap. -0.87%-1.45%+94.92%+45.51%

Financials

2026 *2027 *
Net sales 150M 129M 122M 111M 207M 14.15B 209M 1.44B 559M 7.23B 562M 550M 23.76B 192M 166M 156M 142M 266M 18.18B 268M 1.85B 718M 9.29B 723M 707M 30.53B
Net income -219M -189M -178M -162M -303M -20.67B -305M -2.11B -817M -10.57B -822M -804M -34.72B -185M -160M -151M -137M -257M -17.51B -259M -1.78B -692M -8.95B -696M -681M -29.42B
Net Debt -156M -135M -127M -116M -216M -14.74B -218M -1.5B -583M -7.54B -586M -573M -24.75B -77.38M -66.75M -62.88M -57.29M -107M -7.31B -108M -744M -289M -3.74B -291M -284M -12.28B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
03/09/26 US$2.305 +2.90% 444,880
02/09/26 US$2.240 -3.03% 2,307,870
01/09/26 US$2.310 -1.70% 1,477,729
31/08/26 US$2.350 +0.43% 1,197,017
28/08/26 US$2.340 -0.85% 1,436,887
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.240USD
Average target price
8.725USD
Spread / Average Target
+289.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock